Sosei confident on meeting more milestones under Pfizer collaboration
A link-up announced in 2015 between Sosei Heptares and Pfizer (NYSE: PFE) is starting to bear fruit.
The former company, which is the brand name that the business took on to reflect the link-up of Japanese biopharma Sosei Group (TYO: 4565) and UK-based Heptares Therapeutics, reports encouraging progress and initial success of its strategic multi-target drug discovery collaboration with the US pharma giant.
The research phase of the collaboration has delivered several milestones leading to the advancement of new potental candidate programs against G protein-coupled receptor (GPCR) targets nominated by Pfizer in major disease areas.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze